DelveInsight’s “Diabetic Retinopathy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Diabetic Retinopathy, historical and forecasted epidemiology as well as the Diabetic Retinopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Diabetic Retinopathy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Diabetic Retinopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Diabetic Retinopathy Market Insights
Diabetic Retinopathy Overview
Diabetic retinopathy (DR) is a micro vascular disorder occurring due to long term effects of diabetes, leading to vision-threatening damage to the retina, eventually leading to blindness. Diabetic retinopathy affects people with diagnosed or undiagnosed diabetes mellitus. The propensity of developing diabetic retinopathy is directly proportional to the age of the patient and duration of diabetes as well as with poor glycemic control and fluctuating blood pressure level.
Some of the key facts of the Diabetic Retinopathy Market Report:
- The Diabetic Retinopathy market size was valued at USD 126,851 million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
- According to the American Academy of Ophthalmology, Diabetic retinopathy (DR) results from high blood sugar levels, which cause damage to blood vessels in the retina. This might result in blood vessels swelling and leaking or causing a blockage in blood flow
- According to a meta-analysis on Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045 by Teo et al., there are approximately 93 million patients suffering with DRs, 17 million patients with proliferative DRs, and 21 million patients with diabetic macular edema, worldwide. These data highlight the significant global public health burden of Diabetic Retinopathy
- Key Diabetic Retinopathy Companies: Genentech, Inc., Regeneron Pharmaceuticals, Roche, Kodiak Sciences Inc, Allegro Ophthalmics, LLC, Graybug Vision, Opthea Limited, REGENXBIO Inc., Kodiak Sciences Inc., Novartis, Adverum Biotechnologies, and others
- Key Diabetic Retinopathy Therapies: OPT-302, RGX-314, KSI-301, RTH258, ADVM-022, and others
- The Diabetic Retinopathy epidemiology based on gender analyzed that the prevalence of Diabetic Retinopathy is slightly higher in males as compared to females
Get a Free sample for the Diabetic Retinopathy Market Report –
https://www.delveinsight.com/sample-request/diabetic-retinopathy-market
Key benefits of the Diabetic Retinopathy Market report:
- Diabetic Retinopathy market report covers a descriptive overview and comprehensive insight of the Diabetic Retinopathy Epidemiology and Diabetic Retinopathy market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Diabetic Retinopathy market report provides insights on the current and emerging therapies.
- Diabetic Retinopathy market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Diabetic Retinopathy market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Diabetic Retinopathy market.
Download the report to understand which factors are driving Diabetic Retinopathy epidemiology trends @ Diabetic Retinopathy Epidemiological Insights
Diabetic Retinopathy Market
The dynamics of the Diabetic Retinopathy market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
Diabetic Retinopathy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Diabetic Retinopathy Epidemiology Segmentation:
The Diabetic Retinopathy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Diabetic Retinopathy
- Prevalent Cases of Diabetic Retinopathy by severity
- Gender-specific Prevalence of Diabetic Retinopathy
- Diagnosed Cases of Episodic and Chronic Diabetic Retinopathy
Diabetic Retinopathy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diabetic Retinopathy market or expected to get launched during the study period. The analysis covers Diabetic Retinopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Diabetic Retinopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Discover more about therapies set to grab major Diabetic Retinopathy market share @ Diabetic Retinopathy market forecast
Diabetic Retinopathy Therapies and Key Companies
- OPT-302: Opthea Limited
- RGX-314: REGENXBIO Inc.
- KSI-301: Kodiak Sciences Inc.
- RTH258: Novartis
- ADVM-022: Adverum Biotechnologies
Diabetic Retinopathy Market Strengths
- Different possible pathways have been extensively studied which could be responsible for the disease. Therefore a better understanding has been obtained through years of thorough research and development
Scope of the Diabetic Retinopathy Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Diabetic Retinopathy Companies: Genentech, Inc., Regeneron Pharmaceuticals, Roche, Kodiak Sciences Inc, Allegro Ophthalmics, LLC, Graybug Vision, Opthea Limited, REGENXBIO Inc., Kodiak Sciences Inc., Novartis, Adverum Biotechnologies, and others
- Key Diabetic Retinopathy Therapies: OPT-302, RGX-314, KSI-301, RTH258, ADVM-022, and others
- Diabetic Retinopathy Therapeutic Assessment: Diabetic Retinopathy current marketed and Diabetic Retinopathy emerging therapies
- Diabetic Retinopathy Market Dynamics: Diabetic Retinopathy market drivers and Diabetic Retinopathy market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Diabetic Retinopathy Unmet Needs, KOL’s views, Analyst’s views, Diabetic Retinopathy Market Access and Reimbursement
Diabetic Retinopathy Market Opportunities
- A large patient pool allows companies to make cost effective drugs and realize substantial gains
Table of Contents
1. Diabetic Retinopathy Market Report Introduction
2. Executive Summary for Diabetic Retinopathy
3. SWOT analysis of Diabetic Retinopathy
4. Diabetic Retinopathy Patient Share (%) Overview at a Glance
5. Diabetic Retinopathy Market Overview at a Glance
6. Diabetic Retinopathy Disease Background and Overview
7. Diabetic Retinopathy Epidemiology and Patient Population
8. Country-Specific Patient Population of Diabetic Retinopathy
9. Diabetic Retinopathy Current Treatment and Medical Practices
10. Diabetic Retinopathy Unmet Needs
11. Diabetic Retinopathy Emerging Therapies
12. Diabetic Retinopathy Market Outlook
13. Country-Wise Diabetic Retinopathy Market Analysis (2019–2032)
14. Diabetic Retinopathy Market Access and Reimbursement of Therapies
15. Diabetic Retinopathy Market Drivers
16. Diabetic Retinopathy Market Barriers
17. Diabetic Retinopathy Appendix
18. Diabetic Retinopathy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Diabetic Retinopathy treatment, visit @ Diabetic Retinopathy Medications
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting